Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Wei Zhang, Yuhong Wang, Xin Jiang, Hu Zhao, Xinli Jia, Qiye Wang, Yue Chen, Yuanfang Jiang, Zhifang Ma, Lina Chang & Xin Wang. (2023) Newly identified adverse events for gemcitabine using the Food and Drug Administration Adverse Event Reporting System. Expert Opinion on Drug Safety 0:0, pages 1-7.
Read now
Read now
Articles from other publishers (15)
Gilbert Youssef, Patrick Y. Wen & Eudocia Q. Lee. 2022. Neurological Complications of Systemic Cancer and Antineoplastic Therapy. Neurological Complications of Systemic Cancer and Antineoplastic Therapy
479
500
.
John R. Schaub & Shou-Ching Tang. (2021) Delayed Gemcitabine-Induced Posterior Reversible Encephalopathy Syndrome. The American Journal of the Medical Sciences 361:6, pages 795-798.
Crossref
Crossref
Aristides A. Capizzano, Toshio Moritani, Yang Mao-Draayer, Brian Chang & Deema Fattal. 2021. Diffusion-Weighted MR Imaging of the Brain, Head and Neck, and Spine. Diffusion-Weighted MR Imaging of the Brain, Head and Neck, and Spine
391
428
.
Bernardo Cacho-Díaz, Nydia A. Lorenzana-Mendoza, Karen Salmerón-Moreno, Gervith Reyes-Soto, Carlos Castillo-Rangel, Roberto Corona-Cedillo, Salvador Escobar-Ceballos & Jaime G. de la Garza-Salazar. (2019) Chemotherapy-induced posterior reversible encephalopathy syndrome. Medicine 98:19, pages e15691.
Crossref
Crossref
Chen Makranz, Salome Khutsurauli, Yosef Kalish, Ruth Eliahou, Luna Kadouri, John Gomori & Alexander Lossos. (2017) Neurological variability in chemotherapy‑induced posterior reversible encephalopathy syndrome associated with thrombotic microangiopathy: Case reports and literature review. Molecular and Clinical Oncology.
Crossref
Crossref
Laura K. Hadad & Caroline C. Billingsley. (2017) Posterior reversible encephalopathy syndrome (PRES) associated with ovarian cancer and voltage-gated potassium channel antibodies: A case report. Gynecologic Oncology Reports 20, pages 67-69.
Crossref
Crossref
Hannah Cherniawsky, Neesha Merchant, Micheal Sawyer & Maria Ho. (2017) A case report of posterior reversible encephalopathy syndrome in a patient receiving gemcitabine and cisplatin. Medicine 96:8, pages e5850.
Crossref
Crossref
Meizuo Zhong, Bin Li & Jing Li. (2011) Acute Transverse Myelopathy Probably Related to Intravenous Gemcitabine Plus Cisplatin. Annals of Pharmacotherapy 45:4, pages 544-545.
Crossref
Crossref
Takahiro Maeda, Eiji Kikuchi, Kazuhiro Matsumoto, Satoshi Yazawa, Jun Hagiuda, Akira Miyajima, Ken Nakagawa, Hirokazu Fujiwara, Haruhiko Hoshino & Mototsugu Oya. (2010) Gemcitabine and cisplatin chemotherapy induced reversible posterior leukoencephalopathy syndrome in a bladder cancer patient. International Journal of Clinical Oncology 15:5, pages 508-511.
Crossref
Crossref
C. H. Han & M. P. Findlay. (2010) Chemotherapy-induced reversible posterior leucoencephalopathy syndrome. Internal Medicine Journal 40:2, pages 153-159.
Crossref
Crossref
Anthony Faivre, Christelle Pasqualini, Julien Legodec, Pierre Bounolleau, Trévor Lafolie & Philippe Alla. (2009) Cécité brutale au décours d’un traitement par cisplatine et gemcitabine. La Presse Médicale 38:11, pages 1706-1709.
Crossref
Crossref
Eun Jin KwonSe Won KimKwang Ki KimHyung Suk SeoDo Yeun Kim. (2009) A Case of Gemcitabine and Cisplatin Associated Posterior Reversible Encephalopathy Syndrome. Cancer Research and Treatment 41:1, pages 53.
Crossref
Crossref
Anita Rajasekhar & Thomas J. GeorgeJr.Jr.. (2007) Gemcitabine-Induced Reversible Posterior Leukoencephalopathy Syndrome: A Case Report and Review of the Literature. The Oncologist 12:11, pages 1332-1335.
Crossref
Crossref
Germán Morís, Renee Ribacoba & Carmen González. (2007) Delayed posterior encephalopathy syndrome following chemotherapy with oxaliplatin and gemcitabine. Journal of Neurology 254:4, pages 534-535.
Crossref
Crossref
. (2005) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 14:3.
Crossref
Crossref